PsyBio Therapeutics Corp. PSYBF
0.00 USD 0.00 (+0.00%)
At closeNov 2, 2026, 4:00 PM EST
0.005 Day range 0.005
0.00001 52-week range 0.005
- YTD
- 0.00%
- 1 year
- -90.00%
News
newsfilecorp.com PsyBio Therapeutics Awarded Approval to Manufacture Biosynthetic Tryptamines at Scale PsyBio continues to develop psycho-targeted, biosynthesized tryptamines and with this authorization becomes the first biotechnology company to obtain government sanctioned, formal, written…
benzinga.com Cannabis Movers & Shakers: Burns & Levinson, Water Ways, Chill Brands, Rubicon Organics Burns & Levinson Expands National Cannabis Business Law Practice Boston-based Burns & Levinson LLP announced Tuesday that Max Borg has joined the firm as a partner and Douglas Ginn has joined as an…
proactiveinvestors.com PsyBio Therapeutics successfully completes first pre-IND meeting with the FDA PsyBio Therapeutics Corp has announced the successful completion of its initial pre-Investigational New Drug (IND) application meeting with the US Food and Drug Administration (FDA) as part of the…
proactiveinvestors.com PsyBio Therapeutics presents 16 scientific abstracts highlighting its research and development efforts at two scientific conferences PsyBio Therapeutics Corp said it presented 16 abstracts highlighting the biotechnology company's research and development initiatives at two scientific conferences. The abstracts covered topics such…
proactiveinvestors.com PsyBio Therapeutics shares updates on intellectual property and clinical development milestones PsyBio Therapeutics Corp., a biotechnology company developing a portfolio of psychoactive compounds aimed at the treatment of mental health disorders, told shareholders that it has filed “six…
proactiveinvestors.com PsyBio Therapeutics is developing psychoactive compounds which could be a mental health game changer Has initiated pilot scale-up of its biosynthetic formulation of psilocybin Developing a bacterial biosynthesis process for tryptamine production Well capitalized in an oversubscribed raise What…
proactiveinvestors.com PsyBio Therapeutics announces expansion of its intellectual property portfolio by filing six additional patent applications PsyBio Therapeutics announced that it has filed six additional provisional manufacturing patent applications to expand its intellectual property portfolio. The Oxford, Ohio-based biotech company said…
prnewswire.com PsyBio Therapeutics to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th OXFORD, Ohio and COCONUT CREEK, Fla., Oct. 11, 2021 /PRNewswire/ -- PsyBio Therapeutics Corp. (TSXV: PSYB, OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology…
proactiveinvestors.com PsyBio Therapeutics successfully demonstrates commercial-scale manufacturing feasibility PsyBio Therapeutics Corp. reported that it has demonstrated the ability to manufacture PsyBio-11040, one of its first promising therapeutic candidates, at a commercial scale. The company said this is…
proactiveinvestors.com PsyBio Therapeutics submits its first pre-IND application meeting request to FDA PsyBio Therapeutics Corp. has submitted its first pre-Investigational New Drug (IND) application meeting request to the US Food and Drug Administration as part of the regulatory submission process.
proactiveinvestors.com PsyBio Therapeutics inducted into AdvisorShares Psychedelics ETF PsyBio Therapeutics Corp said it has been included in the AdvisorShares Psychedelics Exchange Traded Fund (ETF). The intellectual property-driven, biotechnology company is currently developing novel,…